Setting aside the commoditisation of the off-patent market, falling wholesale prices and debate over market access arrangements for biosimilars, arguably the sector's biggest strategic issue is the creeping introduction of a PHARMAC-style capped pharmaceutical Budget. …
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 31 October
October 31, 2025 - - Podcast -
Aroa Biosurgery appoints Paul Shearer to Board as John Pinion retires
October 31, 2025 - - Australian Biotech -
Immuron provides update on U.S. clinical trials for Travelan and IMM-529
October 31, 2025 - - Australian Biotech -
Firebrick Pharma launches new Nasodine Throat Spray for international markets
October 31, 2025 - - Australian Biotech -
Amplia Therapeutics begins trading on U.S. OTCQB Venture Market
October 31, 2025 - - Australian Biotech -
DHL Supply Chain opens New Zealand’s most advanced life sciences and healthcare logistics facility
October 31, 2025 - - Latest News -
The continued 'false framing' aims to make us feel guilty for wanting more on health
October 31, 2025 - - Latest News